In swine feed-milling operations where Liansen Zhili Granules Veterinary Grade API is let down from a concentrated premix into complete feed, the controlling variable is not the gross addition rate but the coefficient of variation of the active fraction across the batch. The granulated input enters the premix line with a bulk density typically in the range of 0.45–0.65 g/mL; if two lots arrive with opposite ends of that range, a fixed-mass addition will produce a 5–7% error in delivered active concentration unless the addition is recalculated from the lot assay value. Industry compliance for this route sits at the intersection of EU Regulation 2019/4 for medicated feed, ISO 22000:2018 for feed-safety management, and, in the United States, 21 CFR 558 for new animal drugs in feed. The formulation addition ratio is therefore expressed as a let-down sequence rather than a single percentage: the concentrated premix is prepared at 5–15 kg of granulated API per tonne of carrier, depending on the approved daily dose and assay; the resulting premix is then incorporated at 20 kg per tonne of complete feed for grower pigs as a starting production figure, not as a licensed therapeutic dose. Published data for this specific configuration is limited, so the addition must be recalculated whenever the incoming granule assay or particle-size distribution shifts. The downstream production process begins with geometric dilution: the API granules are first blended with an equal mass of calcium carbonate or wheat middlings in a 100 L bin blender, then sequentially extended through a horizontal paddle or ribbon mixer filled to 40–70% of working volume. Mixing time must be validated for each batch size because the granule’s particle-size distribution can stratify in low-shear cone blenders, with fines migrating toward the discharge port; a CV ≤5% at the premix stage is the standard acceptance target. If the finished feed is pelleted, the conditioning temperature should be held below 65°C unless forced-degradation data on the active fraction support higher exposure. Terminal finished product types from this line include 0.5%, 1%, and 5% medicated premixes, meal-type complete feed, pelleted grower feed, and top-dress granules where the premix is left as a separate application rather than homogeneously mixed.

How Does Compression Pressure Alter Disintegration Time in Ruminant Oral Boluses?

Direct compression of the granulated API into a calf bolus requires moisture below 6.0%, because residual water acts as a plasticizer and increases tablet capping at compression forces above 14 kN. The formulation addition ratio for this route typically ranges from 20% to 45% w/w of the granulated API, with the remainder composed of microcrystalline cellulose 30–50% w/w, lactose monohydrate 15–25% w/w, crospovidone 2–5% w/w, sodium starch glycolate 0–3% w/w, magnesium stearate 0.5–1.5% w/w, and colloidal silicon dioxide 0.2–0.8% w/w. The granulated API should be pre-sieved through a 500 µm screen, and if the Hausner ratio exceeds 1.35, dry granulation by roller compaction is required before tableting because direct compression will otherwise generate weight variability on a high-speed rotary press. The downstream production process relies on a rotary tablet press operating at 20–45 rpm turret speed with a compression force of 12–22 kN; a target tablet breaking force of 80–150 N is measured according to USP <1217>, and friability is held below 1.0% according to the harmonised compendial method. Disintegration time is controlled by USP <701> in simulated rumen buffer at pH 6.2 and 39°C; terminal tablets or boluses that fail to disintegrate within 30 min present a risk of intestinal bypass in pre-ruminant calves, so disintegrant concentration is adjusted before any change in compression force. Compliance for the non-sterile tablet line is anchored to Ph. Eur. 5.1.4 for microbiological quality; if the tablets are marketed in Europe, the product must also satisfy the relevant monograph for veterinary dosage forms and ICH Q3D elemental impurity limits. Terminal finished product types include calf oral tablets, ruminal boluses, and chewable tablets for cattle and sheep.

When the treatment route is flock-level drinking water rather than individual animal dosing, the granulated raw material must be milled or sieved to a particle size that disperses within 120 seconds in water at 10°C, not merely in warm laboratory water. The industry compliance framework for this route includes Ph. Eur. 5.1.4 for non-sterile microbiological quality, Ph. Eur. 2.9.40 for uniformity of dosage units if the finished powder is filled into sachets, and, for food-producing poultry, the applicable maximum residue limits in Commission Regulation (EU) No 37/2010 where the active substance is registered. The formulation addition ratio is calculated on the basis of the granule assay, not raw granule mass: a typical starting formulation disperses 0.5–2.0 kg of the granulated API per 1,000 L of drinking water, adjusted to the approved mg/kg body-weight dose for the target species; in hard water above 300 mg/L CaCO₃ equivalent, a citrate buffer or chelator is added at 0.1–0.3% w/v to prevent insoluble complex formation, which would otherwise reduce the available active fraction and clog nipple drinkers. The downstream production process begins with dry milling of the granules to a target D90 of 250 µm or finer, followed by blending with dextrose monohydrate or lactose in a low-shear ribbon mixer; the blend is then filled into heat-sealed foil pouches because the milled granules are hygroscopic at relative humidity above 60%, and moisture pickup above 5.0% will initiate caking and microbial growth. Terminal finished product types include drinking-water soluble powder, water-dispersible granule sachets, and concentrated oral solution precursors that are diluted on-farm before use.

When the Veterinary API Granules Are Processed into an Injectable Solution, Terminal Sterilisation Is Not the First Variable to Fix

Injectable manufacture from a granulated raw material is constrained by bacterial endotoxin burden, subvisible particle load, and pH shift after reconstitution, and the granulated input is not sterile as received. Compliance for a sterile injectable line is governed by Ph. Eur. 0520 for parenteral preparations, USP <85> for bacterial endotoxins, USP <788> for particulate matter in injections, EU GMP Annex 1 for sterile manufacture, and ICH Q3D for elemental impurities. The formulation addition ratio is expressed against the active fraction, not the whole granule mass: if the granule lot has an assay of 30% active fraction, preparing a 5% w/v active solution would require 16.7% w/v of granules, which is frequently beyond the solubility limit of the matrix and produces unacceptable viscosity. The downstream production process therefore begins with dissolution in Water for Injection at 35–50°C under high-shear mixing, followed by pH adjustment with 0.1 N hydrochloric acid or sodium hydroxide, clarification with 0.1% w/w activated carbon for 30 min, and sequential filtration through 5 µm, 0.45 µm, and 0.22 µm membranes under nitrogen blanketing. Terminal sterilisation at 121°C for 15 min may be used only if forced-degradation studies demonstrate no increase in subvisible particles and no stability loss of the active fraction; otherwise, aseptic filtration into sterile vials is required. The operational boundary is narrow: polysaccharide or tannin fractions in the granule matrix can foul 0.22 µm membranes, and filter capacity must be established by Vmax testing rather than fixed batch volume. Terminal finished product types include single-dose ampoules, multi-dose vials for cattle and swine, and sterile injectable solutions for dilution before administration.

Companion Animal Capsule Filling Without Uniform Particle Size Control

Unlike premix production, capsule filling places a narrower specification on granule size distribution because the dosator or tamping pin mechanism cannot compensate for cohesive powders at high fill speeds. The addition ratio in this route commonly ranges from 2.5% to 40% w/w of the granulated API in the final capsule fill, with the remainder composed of microcrystalline cellulose, pregelatinised starch, and magnesium stearate at 0.5% w/w; if the API granules are milled too finely, the formulation may require dry granulation to prevent segregation. Compliance is anchored to Ph. Eur. 5.1.4, USP <1174> for powder flow, USP <905> for uniformity of dosage units, and ICH Q3D for elemental impurities. The downstream production process is performed on an automatic capsule filler operating with pin or dosator settings; incoming granules are milled to a D90 of 250 µm or lower and blended for 10–15 min in a bin blender before filling. Fill weight is monitored every 15–20 min against the target mass, and moisture is held below 5.0% to prevent capsule shell brittleness or softening. Terminal finished product types include hard gelatin capsules and hydroxypropyl methylcellulose capsules for companion-animal dosing, often in 50 mg, 100 mg, and 250 mg fill-weight presentations labelled by active-fraction content rather than granule mass.

Direct repackaging of the supplied granules into finished oral sachets is rarely acceptable without a particle-size conditioning step, because the incoming bulk density and agglomerate strength determine whether the dose can be delivered with a volumetric filler at acceptable weight variability. The relevant compliance framework for finished oral granules includes Ph. Eur. 5.1.4, Ph. Eur. 2.9.40 for uniformity of dosage units, and USP <905> where compendial alignment is required; if the product is presented as a top-dress, the same non-sterile microbiological limits apply as for oral powders. The formulation addition ratio is set by the intended presentation: for a 100% w/w direct-fill granule product, a flow aid such as colloidal silicon dioxide is added at 0.2–0.5% w/w to reduce interparticle friction; for a diluted oral granule, the active granule fraction is typically 20–80% w/w in a maltodextrin or lactose carrier. The downstream production process begins with a 1.0 mm sieve to remove oversize agglomerates, followed by low-shear blending for 8–12 min and sachet filling on a vertical form-fill-seal line; fill-weight tolerance is maintained at ±5% of the target, and the line is paused for cleaning if the environmental relative humidity exceeds 60% because the granule matrix will absorb moisture and become tacky. Terminal finished product types include single-dose oral sachets, multi-day top-dress granules for swine and poultry, and bulk oral granule containers for veterinary practice dispensing.